{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:20:23Z","timestamp":1767925223882,"version":"3.49.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Abbott Diagnostics Division Research and Development"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Long-term studies of vaccine recipients are necessary to understand severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody durability and assess the impact of booster doses on antibody levels and protection from infection. The identification of vaccine breakthrough infections among fully vaccinated populations will be important in understanding vaccine efficacy and SARS-CoV-2 vaccine escape capacity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>SARS-CoV-2 spike (S) receptor-binding domain and nucleocapsid (N) immunoglobulin (Ig) G levels were measured in a longitudinal study of 1000 Chicago healthcare workers who were infection naive or previously infected and then vaccinated. Changes in S and N IgG were followed up through 14 months, and vaccine breakthrough infections were identified by increasing levels of N IgG.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>SARS-CoV-2 S IgG antibody levels among previously infected and previously noninfected individuals decreased steadily for 11 months after vaccination. Administration of a booster 8\u201311 months after vaccination increased S IgG levels &amp;gt;2-fold beyond those observed after 2 doses, resulting in S IgG levels that were indistinguishable between previously infected and uninfected individuals. Increases in N IgG identified vaccine breakthrough infections and showed &amp;gt;15% breakthrough infection rates during the Omicron wave starting in December 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results demonstrate SARS-CoV-2 antibody changes after vaccination and breakthrough infections and identify high levels of vaccine breakthrough infections during the Omicron wave, based on N IgG increases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiac420","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T10:01:44Z","timestamp":1666260104000},"page":"1934-1942","source":"Crossref","is-referenced-by-count":12,"title":["Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G"],"prefix":"10.1093","volume":"226","author":[{"given":"Mark","family":"Anderson","sequence":"first","affiliation":[{"name":"Abbott Diagnostics Division, Abbott Laboratories , Abbott Park, Illinois , USA"},{"name":"Abbott Diagnostics Division, Abbott Pandemic Defense Coalition , Abbott Park, Illinois , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Stec","sequence":"additional","affiliation":[{"name":"Abbott Diagnostics Division, Abbott Laboratories , Abbott Park, Illinois , USA"},{"name":"Abbott Diagnostics Division, Abbott Pandemic Defense Coalition , Abbott Park, Illinois , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Gosha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rush University Medical Center , Chicago, Illinois , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taha","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rush University Medical Center , Chicago, Illinois , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Boler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rush University Medical Center , Chicago, Illinois , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca","family":"Tojo Suarez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rush University Medical Center , Chicago, Illinois , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dylan","family":"Behun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rush University Medical Center , Chicago, Illinois , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Landay","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rush University Medical Center , Chicago, Illinois , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Cloherty","sequence":"additional","affiliation":[{"name":"Abbott Diagnostics Division, Abbott Laboratories , Abbott Park, Illinois , USA"},{"name":"Abbott Diagnostics Division, Abbott Pandemic Defense Coalition , Abbott Park, Illinois , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Moy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rush University Medical Center , Chicago, Illinois , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"2022112816393897100_jiac420-B1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(21)00475-8","article-title":"Hospital admission and emergency care attendance risk for SARS-CoV-2 Delta (B.1.617.2) compared with Alpha (B.1.1.7) variants of concern: a cohort study","volume":"22","author":"Twohig","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2022112816393897100_jiac420-B2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ajpath.2022.01.007","article-title":"Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the Omicron variant of severe acute respiratory syndrome coronavirus 2 in Houston, Texas","volume":"192","author":"Christensen","year":"2022","journal-title":"Am J Pathol"},{"key":"2022112816393897100_jiac420-B3","author":"UK Health Security Agency"},{"key":"2022112816393897100_jiac420-B4","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"2022112816393897100_jiac420-B5","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N Engl J Med"},{"key":"2022112816393897100_jiac420-B6","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against COVID-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"key":"2022112816393897100_jiac420-B7","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.mayocp.2022.02.002","article-title":"Identification of natural SARS-CoV-2 infection in seroprevalence studies among vaccinated populations","volume":"97","author":"Demmer","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"2022112816393897100_jiac420-B8","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-021-04117-7","article-title":"Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants","volume":"600","author":"Andreano","year":"2021","journal-title":"Nature"},{"key":"2022112816393897100_jiac420-B9","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.cell.2022.03.018","article-title":"Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity","volume":"185","author":"Rodda","year":"2022","journal-title":"Cell"},{"key":"2022112816393897100_jiac420-B10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/infdis\/jiac261","article-title":"Neutralizing antibody activity to SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) after one and two doses of BNT162b2 vaccine in infection-na\u00efve and previously-infected individuals","volume":"226","author":"Moy","year":"2022","journal-title":"J Infect Dis"},{"key":"2022112816393897100_jiac420-B11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2022112816393897100_jiac420-B12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.19741","article-title":"SARS-CoV-2 antibody responses in infection-naive or previously infected individuals after 1 and 2 doses of the BNT162b2 vaccine","volume":"4","author":"Anderson","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2022112816393897100_jiac420-B13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annepidem.2020.06.004","article-title":"Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York","volume":"48","author":"Rosenberg","year":"2020","journal-title":"Ann Epidemiol"},{"key":"2022112816393897100_jiac420-B14","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00941-20","article-title":"Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho","volume":"58","author":"Bryan","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2022112816393897100_jiac420-B15","doi-asserted-by":"crossref","first-page":"1256.e9","DOI":"10.1016\/j.cmi.2020.05.036","article-title":"Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection","volume":"26","author":"Chew","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2022112816393897100_jiac420-B16","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1001\/jama.2021.6042","article-title":"Spike antibody levels of nursing home residents with or without prior COVID-19 3 weeks after a single BNT162b2 vaccine dose","volume":"325","author":"Blain","year":"2021","journal-title":"JAMA"},{"key":"2022112816393897100_jiac420-B17","author":"Chicago Department of Public Health"},{"key":"2022112816393897100_jiac420-B18","doi-asserted-by":"crossref","first-page":"104765","DOI":"10.1016\/j.jcv.2021.104765","article-title":"Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection","volume":"136","author":"Van Elslande","year":"2021","journal-title":"J Clin Virol"},{"key":"2022112816393897100_jiac420-B19","doi-asserted-by":"crossref","first-page":"104008","DOI":"10.1016\/j.ebiom.2022.104008","article-title":"The displacement of the SARS-CoV-2 variant Delta with Omicron: an investigation of hospital admissions and upper respiratory viral loads","volume":"79","author":"Fall","year":"2022","journal-title":"EBioMedicine"},{"key":"2022112816393897100_jiac420-B20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"2022112816393897100_jiac420-B21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"2022112816393897100_jiac420-B22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"2022112816393897100_jiac420-B23","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cell.2022.01.019","article-title":"Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron","volume":"185","author":"Cui","year":"2022","journal-title":"Cell"},{"key":"2022112816393897100_jiac420-B24","doi-asserted-by":"crossref","first-page":"830527","DOI":"10.3389\/fimmu.2021.830527","article-title":"Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies","volume":"12","author":"Shah","year":"2021","journal-title":"Front Immunol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiac420\/46714024\/jiac420.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/11\/1934\/47369534\/jiac420.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/11\/1934\/47369534\/jiac420.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T16:41:12Z","timestamp":1669653672000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/11\/1934\/6764413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,10,20]]},"published-print":{"date-parts":[[2022,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac420","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,10,20]]}}}